Pluri Overview
- Year Founded
-
2003
- Status
-
Public
- Employees
-
113
- Stock Symbol
-
PLUR
- Investments
-
4
- Share Price
-
$1.05
- (As of Friday Closing)
Pluri General Information
Description
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
Contact Information
Website
www.pluri-biotech.comCorporate Office
- Matam Park Building 5
- Haifa 3508409
- Israel
Corporate Office
- Matam Park Building 5
- Haifa 3508409
- Israel
Pluri Timeline
Pluri Stock Performance
As of 13-Nov-2026, Pluri’s stock price is $1.05. Its current market cap is $15.1M with 14.4M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.05 | $1.09 | $0.85 - $4.29 | $15.1M | 14.4M | 36.4K | -$2.44 |
Pluri Financials Summary
As of 30-Jun-2026, Pluri has a trailing 12-month revenue of $1.02M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2026 30-Jun-2026 | FY 2025 30-Jun-2025 | FY 2024 30-Jun-2024 |
|---|---|---|---|---|
| EV | 52,460 | 52,460 | 48,833 | 37,424 |
| Revenue | 1,016 | 1,016 | 1,336 | 326 |
| EBITDA | (24,439) | (24,439) | (23,210) | (21,631) |
| Net Income | (23,821) | (23,821) | (22,583) | (20,888) |
| Total Assets | 24,878 | 24,878 | 38,683 | 39,527 |
| Total Debt | 34,914 | 34,914 | 34,050 | 29,612 |
Pluri Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Pluri Comparisons
Industry
Financing
Details
Pluri Competitors (16)
One of Pluri’s 16 competitors is Regenxbio, a Formerly VC-backed company based in Rockville, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Regenxbio | Formerly VC-backed | Rockville, MD | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| Protagonist Therapeutics | Formerly VC-backed | Newark, CA | ||||
| AnGes | Formerly VC-backed | Osaka, Japan | ||||
| NewcelX | Corporate Backed or Acquired | Kloten, Switzerland |
Pluri Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Pluri Patents
Pluri Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20190167133-A1 | Wireless biological interface platform | Inactive | 15-Jun-2016 | ||
| WO-2017218752-A1 | Wireless biological interface platform | Inactive | 15-Jun-2016 | ||
| WO-2007108003-A2 | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy | Inactive | 23-Mar-2006 | ||
| WO-2007091255-A2 | Method and apparatus for maintenance and expansion of hematopoietic stem cells from mononuclear cells | Inactive | 06-Feb-2006 | ||
| US-20050180958-A1 | Using plug flow bioreactor system which mimics bone marrow microenvironment for propagation and maintenance of stromal cells; transplanting undifferentiated hemopoietic stem cells into a recipient | Inactive | 04-Feb-1999 | C12N5/0647 |
Pluri Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Pluri Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Pluri Investments & Acquisitions (4)
Pluri’s most recent deal was a Merger/Acquisition with Zeo ScientifiX. The deal was made on 26-Oct-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Zeo ScientifiX | 26-Oct-2026 | Merger/Acquisition | Biotechnology | ||
| Kokomodo | 28-Apr-2025 | Merger/Acquisition | Biotechnology | ||
| Ever After Foods | 24-Feb-2022 | Joint Venture | Biotechnology | ||
| A.I. Software | 10-Jun-2003 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) |
Pluri ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Pluri Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Kokomodo | Haifa, Israel | 2024 |
Pluri FAQs
-
When was Pluri founded?
Pluri was founded in 2003.
-
Where is Pluri headquartered?
Pluri is headquartered in Haifa, Israel.
-
What is the size of Pluri?
Pluri has 113 total employees.
-
What industry is Pluri in?
Pluri’s primary industry is Biotechnology.
-
Is Pluri a private or public company?
Pluri is a Public company.
-
What is Pluri’s stock symbol?
The ticker symbol for Pluri is PLUR.
-
What is the current stock price of Pluri?
As of 13-Nov-2026 the stock price of Pluri is $1.05.
-
What is the current market cap of Pluri?
The current market capitalization of Pluri is $15.1M.
-
What is Pluri’s current revenue?
The trailing twelve month revenue for Pluri is $1.02M.
-
Who are Pluri’s competitors?
Regenxbio, Genetix Biotherapeutics, Protagonist Therapeutics, AnGes, and NewcelX are some of the 16 competitors of Pluri.
-
What is Pluri’s annual earnings per share (EPS)?
Pluri’s EPS for 12 months was -$2.44.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
